Valerio Therapeutics enters exclusive R&D collaboration with Abivax, secures up to €2.4 million upfront

PUBT · 2d ago
Valerio Therapeutics enters exclusive R&D collaboration with Abivax, secures up to €2.4 million upfront
  • Valerio Therapeutics entered a binding term sheet with Abivax for an exclusive global R&D collaboration in immune-mediated inflammatory diseases.
  • Valerio to receive upfront payment up to EUR 2.4 million; eligible for development and commercial milestones plus royalties on net sales.
  • Collaboration covers identification, design, manufacturing, preclinical testing of candidates; Abivax may take selected programs into further development.
  • Definitive co-ownership and license agreement still pending; transaction positioned as non-dilutive funding for Valerio’s precision RNA pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valerio Therapeutics SA published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.